【2h】

Two Cases of the Emerging

机译:两个案例的新兴

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Candida auris is an opportunistic multidrug-resistant pathogen that was first isolated in 2009 and has since been reported from about 30 countries. In Saudi Arabia, only four cases of C. auris have previously been reported; here, we report two new cases of this infection. Both patients were polymorbid and had long hospitalization periods with recurrent intensive care unit (ICU) admissions. The findings of the tissue/blood cultures and antimicrobial therapy protocols are explained in the case report. Urine culture in both cases was positive for C. auris, and the colonies grew well at 42°C. The fungal isolates were confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The first patient was treated with the recommended dose of caspofungin, but he passed away. The second patient was also planned to be treated with caspofungin, but he passed away before the treatment could be initiated. The present cases further corroborate signs of a growing number of reports of C. auris in patients with high-risk factors, such as hospitalization in ICU, multiple chronic conditions and prolonged antimicrobial treatment exposure. It also highlights the need for hospitals to further improve their infection control practices to prevent nosocomial infections such as C. auris.
机译:Candida Auris是一个机会主义的多药抗性病原体,于2009年首次孤立,并已从大约30个国家报告。在沙特阿拉伯,此前只报告了4例C. Auris;在这里,我们报告了两个感染的新病例。两名患者都是多元化的,并具有经常性的重症监护室(ICU)入院时间(ICU)。在案例报告中解释了组织/血液培养和抗微生物治疗方案的结果。两种病例中的尿培养对于C.Auris是阳性的,并且菌落在42℃下生长良好。通过基质辅助激光解吸电离飞行时间质谱法确认真菌分离物。第一个患者用推荐剂量的Caspofung治疗,但他通过了。第二名患者还计划用Caspofungin治疗,但在可以启动治疗之前他通过了。本病例进一步证实了高风险因素的患者越来越多的C.Auris报告的迹象,例如ICU住院,多重慢性病和长期抗菌治疗暴露。它还强调了医院的需要进一步改善其感染控制实践,以防止医院感染如C. auris。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号